

## 6. LITERATURVERZEICHNIS

1. Strödter D: *Therapie der Herzinsuffizienz*. Bremen: UNI-MED,2000.
2. The Task Force on Heart Failure of the European Society of Cardiology: Guidelines for the diagnosis of heart failure. *Eur Heart J* 1995;18:741-51
3. Erdmann E (Hrsg.): *Herzinsuffizienz: Ursachen, Pathophysiologie und Therapie*. Stuttgart: Wissenschaftliche Verlagsgesellschaft,2000.
4. Cleland JGF, Swedberg K, Poole-Wilson PA: Successes and failures of current treatment of heart failure. *Lancet* 1998;352:19-28.
5. Vasan RS, Benjamin EJ, Levy D: Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. *J Am Coll Cardiol* 1995;26: 1565-74.
6. Torre-Amione G: The syndrome of heart failure: emerging concepts in the understanding of its pathogenesis and treatment. *Curr Opin Cardiol* 1999;14: 193-95
7. Cleland JGF, Clark A: Has the survival of the heart failure population changed? Lessons from trials. *Am J Cardiol* 1999;83:112D-119D.
8. Ho KKL, Anderson KM, Kannel WB, Grossmann W, Levy D: Survival after the onset of congestive heart failure in Framingham heart study subjects. *Circulation* 1993;88:107-15.
9. Massie BM, Shah NB: The heart failure epidemic: magnitude of the problem and potential mitigating approaches. *Curr Opin Cardiol* 1996;11:221-26.
10. Kannel WB, Ho K, Thom T: Changing epidemiological features of cardiac failure. *Br Heart J* 1994;72(Suppl):S3-9.
11. Schocken DD, Arrieta MI, Leaverton PE, Ross EA: Prevalence and mortality rate of congestive heart failure in the United States. *JACC* 1992;20:301-6.
12. Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is it? *Eur Heart J* 2001;22:623-6.
13. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population. The Rotterdam Study *Eur Heart J* 1999;20:447-55.
14. Davies MK, Hobbs FD, Davies RC, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. *Lancet* 2001;358:439-44.
15. McKee PA, Castelli WP, McNamara PM, Kannel WB: The natural history of congestive heart failure: the Framingham study. *N Engl J Med* 1971;285:1141-46.
16. Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. *Circulation* 2006;113:799-805.
17. Kannel WB, Belanger AJ: Epidemiology of heart failure. *Am Heart J* 1991;121: 951-57

18. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med* 1991; 325:293-302.
19. Garg RG, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors in patients with heart failure. *JAMA* 1995;273:1450-56.
20. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Study (CONSENSUS). *N Engl J Med* 1987;316:1420-35.
21. St John Sutton M, Pfeffer MA, Moye L et al: Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival And Ventricular Enlargement (SAVE) trial. *Circulation* 1997;96:3294-99.
22. Konstam MA: Role of angiotensin converting enzyme inhibitors in preventing left ventricular remodeling following myocardial infarction. *Eur Heart J* 1995, 16(Suppl K):42-48.
23. Doughty RN, Rodgers A, Sharpe N, McMahon S: Effects of beta-blocker therapy on mortality in patients with heart failure: a systematic overview of randomized controlled trials. *Eur Heart J* 1997;18:560-65.
24. Hall SA, Cigarroa CG, Marcoux L et al: Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. *J Am Coll Cardiol* 1995;25:1154-61.
25. Packer M, Bristow MR, Cohn JN et al: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. *N Engl J Med* 1996;334:1349-55.
26. Waagstein F, Bristow MR, Swedberg K et al: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. *Lancet* 1993;342:1441-46.
27. Doughty RN, Whalley GA, Gamble G, McMahon S, Sharpe N: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. *J Am Coll Cardiol* 1997;29:1060-66.
28. CIBIS Investigators and Committees: A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). *Circulation* 1994;90: 1765-73.
29. Taylor DO, Edwards LB, Boucek MM, et al. The registry of the International Society for Heart and Lung Transplantation: twenty-first official adult heart transplant report 2004. *J Heart Lung Transplant* 2004;23:796-803.
30. Zaroff JG, Babcock WD, Shiboski SC. The impact of left ventricular dysfunction on cardiac donor transplant rates. *J Heart Lung Transplant* 2003;22:334-7.
31. Deng MC, DeMeester JM, Smits JM, et al. Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratified by heart failure severity. Comparative Outcome and Clinical Profiles in Transplantation (COCPIT) study group. *BMJ* 2000;321:540-5.
32. Batista RJ, Santos JL, Takeshita N, et al. Partial left ventriculectomy to improve left ventricular function in end-stage heart disease. *J Card Surg* 1996;11:96-97.

33. Konertz W, Khoynezhad A, Sidiropoulos A, et al. Early and intermediate results of left ventricular reduction surgery. *Eur J Cardio-Thorac Surg* 1999;15(Suppl 1): S26-30.
34. Claus M, Beling M, Grohmann A, et al. Long-term results after partial left ventriculectomy. *Int J Cardiol* 2003;89:223-30.
35. McCarthy JF, McCarthy PM, Starling RC, et al. Partial left ventriculectomy and mitral valve repair for end-stage congestive heart failure. *Eur J Cardio-thorac Surg* 1998;13:337-43.
36. Popovic Z, Miric M, Nescovic AN, et al. Functional capacity late after partial left ventriculectomy: relation to ventricular geometry and performance. *Eur J Cardiothorac Surg* 2001;19:61-7.
37. Suma H, Isomura T, Horii T, et al. Left ventriculoplasty for non-ischemic cardiomyopathy with severe heart failure in 70 patients. *J Cardiol* 2001;37:1-10.
38. Moreira LFP, Stolf NAG, Oliveira SA, et al. Current perspectives of partial left ventriculectomy in the treatment of dilated cardiomyopathy. *Eur J Cardio-Thorac Surg* 2001;19:54-60.
39. Franco-Cereceda A, McCarthy PM, Blackstone EH, Starling RC, et al. Partial left ventriculectomy for dilated cardiomyopathy: Is this an alternative to transplantation? *J Thorac Cardiovasc Surg* 2001;121:879-93.
40. Carpentier A, Chachques JC: Myocardial substitution with a stimulated skeletal muscle: first successful clinical case. *Lancet* 1985;8440:1267.
41. Furnary AP, Jessup M, Moreira LFP: Multicenter trial of dynamic cardiomyoplasty for chronic heart failure. The American Cardiomyoplasty Group. *J Am Coll Cardiol* 1995;28:1175-80.
42. Carpentier A, Chachques JC, Acar C et al: Dynamic cardiomyoplasty at seven years. *J Thorac Cardiovasc Surg* 1993;106:42-52.
43. El Oakley RM, Jarfis JC: Cardiomyoplasty. A critical review of experimental and clinical results. *Circulation* 1994;90:2085-90.
44. Jatene AD, Moriera LFP, Stolf NAG et al: Left ventricular function changes after cardiomyoplasty in patients with dilated cardiomyopathy. *J Thorac Cardiovasc Surg* 1991;102:132-39.
45. Oh JH, Badhwar V, Chiu RC: Mechanisms of dynamic cardiomyoplasty: current concepts. *J Card Surg* 1996;11:194-99.
46. Capouya ER, Gerber RS, Drinkwater DC et al: Girdling effect of nonstimulated cardiomyoplasty on left ventricular function. *Ann Thorac Surg* 1993;56:867-71.
47. Kass DA, Baughman KL, Pak PH et al: Reverse remodeling from cardiomyoplasty in human heart failure: external constraint versus active assist. *Circulation* 1995; 91:2314-18.
48. Patel HJ, Polidori DJ, Pilla JJ et al: Stabilization of chronic remodeling by asynchronous cardiomyoplasty in dilated cardiomyopathy: effects of a conditioned muscle wrap. *Circulation* 1997;96:3665-71
49. Mott BD, Oh JH, Misawa Y et al: Mechanisms of cardiomyoplasty: comparative effects of adynamic versus dynamic Cardiomyoplasty. *Ann Thorac Surg* 1998;65: 1039-45.

50. Cheng W, David BS, Avila RA et al: Cardiomyoplasty: unstimulated latissimus dorsi muscle wrap reduces cardiac output. *Surg Forum* 1992;43:228-31.
51. Vaynblat M, Chiavarelli M, Shah HR et al: Cardiac binding in experimental heart failure. *Ann Thorac Surg* 1997;64:81-85.
52. Oh JH, Badhwar V, Mott BD, Li CM, Chiu RCJ: The effects of prosthetic cardiac binding and adynamic cardiomyoplasty in a model of dilated cardiomyopathy. *J Thorac Cardiovasc Surg* 1998;116:148-53.
53. Shah HR; Vaynblat M, Saliccioli L et al: Composite cardiac binding in experimental heart failure. *Ann Thorac Surg* 2000;69:429-31.
54. Sabbah HN, Chaudhry PA, Paone G, Mishima T, Alferness CA: Passive ventricular constraint with the Acorn prosthetic jacket prevents progressive left ventricular dilation and improves ejection fraction in dogs with moderate heart failure (abstr). *J Am Coll Cardiol* 1999;33(Suppl A):208A.
55. Chaudhry PA, Mishima T, Sharov VG et al: Passive epicardial containment prevents ventricular remodeling in heart failure. *Ann Thorac Surg* 2000;70:1275-1280.
56. Power JM, Raman J, Dornom A et al: Passive ventricular constraint amends the course of heart failure: a study in an ovine model of dilated cardiomyopathy. *Cardiovasc Res* 1999;44:549-55.
57. Sabbah HN, Maltsev VA, Chaudhry PA et al: Contractile function of cardiomyocytes isolated from dogs with heart failure is enhanced after chronic therapy with passive ventricular constraint using the Acorn Cardiac Support Device (abstr). *Circulation* 1999;100(Suppl):439.
58. Chaudry PA, Mishima T, Sharov VG et al: Passive epicardial containment prevents ventricular remodeling in heart failure. *Ann Thorac Surg* 2000;70:1275-80.
59. Sabbah HN, Gupta RC, Sharov VG et al: Prevention of progressive left ventricular dilation with the Acorn Cardiac Support Device (CSD) downregulates stretch-mediated p21ras, attenuates myocyte hypertrophy and improves sarcoplasmic reticulum calcium cycling in dogs with heart failure (abstr). *Circulation* 2000; 102(Suppl):II-683.
60. Gupta RC, Sharov VG, Mishra S, Todor A, Sabbah HN: Chronic therapy with the Acorn Cardiac Support Device (CSD) attenuates cardiomyocyte apoptosis in dogs with heart failure (abstr). *J Am Coll Cardiol* 2001;37(Suppl A):478A.
61. Böhmeke T: *Checkliste Echokardiographie*. Stuttgart; New York: Thieme, 2001.
62. Horii T, Isomura T, Komeda M, Suma H. Left ventriculoplasty for nonischemic dilated cardiomyopathy. *J Card Surg* 2003;18:121-4.
63. Chachques JC, Marino JP, Carpentier A, et al. Dynamic cardiomyoplasty: Clinical follow-up at 12 years. *Eur J Cardio-Thorac Surg* 1997;12:560-8.
64. Lorusso R, Milan E, Alfieri O, et al. Cardiomyoplasty as an isolated procedure to treat refractory heart failure. *Eur J Cardio-Thorac Surg* 1997;11:363-72.
65. Magovern GJ, Simpson KA. Clinical Cardiomyoplasty: Review of the ten-year United States experience. *Ann Thorac Surg* 1996;61:413-9.
66. Qualitätssicherung Herzchirurgie. Bundesauswertung 6.0 2003. *Bundesgeschäftsstelle Qualitätssicherung* 2004.

67. Tabet JY, Metra M, Thabut, G, et al. Prognostic value of cardiopulmonary exercise variables in chronic heart failure patients with or without beta-blocker therapy. *Am J Cardiol* 2006;98:500-3.
68. Kleber FX, Vietzke G, Wernecke KD, et al. Impairment of ventilatory efficiency in heart failure. Prognostic impact. *Circulation* 2000;101:2803-9.
69. Heidenreich PA, Spertus JA, Williams RE, et al. Health status identifies heart failure outpatients at risk for hospitalization or death. *J Am Coll Cardiol* 2006;47:752-6.
70. Sabbah HN, Sharov VG, Gupta RC, et al. Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. *Circ Res* 2003;93:1095-101.
71. Rastogi S, Gupta RC, Mishra S, et al. Long-term therapy with the Acorn cardiac support device normalizes gene expression of growth factors and gelatinases in dogs with heart failure. *J Heart Lung Transplant* 2005;24:1619-25.
72. Rastogi S, Mishra S, Gupta RC, et al. Reversal of maladaptive gene program in left ventricular myocardium of dogs with heart failure following long-term therapy with the Acorn cardiac support device. *Heart Failure Reviews* 2005;10:157-63.
73. Sharov VG, Todor AV, Sabbah HN. Left ventricular histomorphometric findings in dogs with heart failure treated with the Acorn cardiac support device. *Heart Failure Reviews* 2005;10:141-47.
74. Gummert JF, Rahmel A, Mohr FW, et al. The Acorn Cardiac Support Device (CSD) randomized trial: Perioperative results and early follow-up in 26 Patients – a single center experience (abstract). *J Heart Lung Transplant* 2002;21:126-7.
75. Livi U, Alfieri O, Vitali E, et al. One-year clinical experience with the Acorn CorCap cardiac support device: Results of a limited market release safety study in Italy and Sweden. *Ital Heart J* 2005;6:59-65.
76. Douglas PS, Morrow R, Ioli A, Reichek N. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. *J Am Coll Cardiol* 1989;13:311-5.
77. Wong M, Staszewsky L, Cohn JN, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure. Valsartan heart failure trial (Val-HeFT) echocardiographic data. *J Am Coll Cardiol* 2004;43:2022-7.
78. Lee TH, Hamilton MA, Stevenson LW, et al. Impact of left ventricular cavity size on survival in advanced heart failure. *Am J Cardiol* 1993;72:672-6.
79. Sutton MStJ, Pfeffer MA, Braunwald E, et al. Acute myocardial infarction/antiplatelet and thrombolytic therapy: Quantitative echocardiographic measurements are major predictors of adverse cardiovascular events after myocardial infarction: The protective effects of captopril. *Circulation* 1994;89:68-75.
80. Vasan RS, Larson MG, Levy D, et al. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. *N Engl J Med* 1997;336:1350-5.
81. Solomon SD, Anavekar N, Pfeffer MA, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. *Circulation* 2005;112:3738-44.

82. Thohan V. Prognostic implications of echocardiography in advanced heart failure. *Curr Opin Cardiol* 2004;19:238-49.
83. Lembcke A, Wiese TH, Dushe S, et al. Effects of passive cardiac containment on left ventricular structure and function: Verification by volume and flow measurements. *J Heart Lung Transplant* 2004;23:11-19.
84. Lembcke A, Dushe S, Dohmen PM, et al. Early and late effects of passive epicardial constraint on left ventricular geometry: Ellipsoidal re-shaping confirmed by electron-beam computed tomography. *J Heart Lung Transplant* 2006;25:90-8.
85. Trichon BH, Felker M, O'Connor CM, et al. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. *Am J Cardiol* 2003;91:538-43.
86. Robbins JD, Maniar PB, Gheorgiade M, et al. Prevalence and severity of mitral regurgitation in chronic systolic heart failure. *Am J Cardiol* 2003;91:360-2.
87. Koelling TM, Aaronson KD, Armstrong WF, et al. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. *Am Heart J* 2002;144:524-9.
88. Schroder JN, Williams ML, Milano CA, et al. Impact of mitral valve regurgitation evaluated by intraoperative transesophageal echocardiography on long-term outcomes after coronary artery bypass grafting. *Circulation* 2005;112(suppl I):I-293-8.
89. David TE, Uden DE, Strauss HD. The importance of the mitral apparatus in left ventricular function after correction of mitral regurgitation. *Circulation* 1983;68(suppl II):II-76-82.
90. Lee EM, Shapiro LM, Wells FC. Importance of subvalvular preservation and early operation in mitral valve surgery. *Circulation* 1996;94:2117-23.
91. Bishay ES, McCarthy PM, Cosgrove DM, Blackstone EH, et al. Mitral valve surgery in patients with severe left ventricular dysfunction. *Eur J Cardio-thorac Surg* 2000;17:213-21.
92. Chen FY, Adams DH, Cohn LH, et al. Mitral valve repair in cardiomyopathy. *Circulation* 1998;98(suppl II):II-124-7.
93. Gummert JF, Rahmel A, Mohr FW, et al. Mitral valve repair in patients with end stage cardiomyopathy: who benefits? *Eur J Cardio-thorac Surg* 2003;23:1017-22.
94. Bolling SF, Pagani FD, Deeb GM, Bach DS. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. *J Thorac Cardiovasc Surg* 1998;115:381-6.
95. Romano MA, Bolling SF. Update on mitral repair in dilated cardiomyopathy. *J Card Surg* 2004;19:396-400.
96. Boltwood CM, Tei C, Wong M, et al. Quantitative echocardiography of the mitral complex in dilated cardiomyopathy: The mechanism of functional mitral regurgitation. *Circulation* 1983;68:498-508.
97. Wu AH, Aaronson KD, Bolling SF, Koelling TM, et al. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic function. *J Am Coll Cardiol* 2005;45:381-7.

98. Capomolla S, Febo O, Gnemmi M, et al. Beta-blockade therapy in chronic heart failure: Diastolic function and mitral regurgitation improvement by carvedilol. *Am Heart J* 2000;139:596-608.
99. Kono T, Sabbah HN, Rosman H, et al. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. *J Am Coll Cardiol* 1992;20:1594-8.
100. Yiu SF, Enriquez-Sarano M, Tajik AJ, et al. Determinants of the degree of functional mitral regurgitation in patients with systolic left ventricular dysfunction. A quantitative clinical study. *Circulation* 2000;102:1400-6.
101. deGroote P, Millaire A, Foucher-Hossein C, et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. *J Am Coll Cardiol* 1998;32:948-54.
102. DiSalvo TG, Mathier M, Semigran MJ, et al. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. *J Am Coll Cardiol* 1995;25:1143-53.
103. Zornoff LA, Skali H, Pfeffer MA, et al. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. *J Am Coll Cardiol* 2002;39:1450-5.
104. Ghio S, Recusani F, Klersy C, et al. Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. *Am J Cardiol* 2000;85:837-42.
105. Lembcke A, Dushe S, Sonntag S, et al. Changes in right ventricular dimensions and performance after passive cardiac containment. *Ann Thorac Surg* 2004;78:900-5.
106. Rihal CS, Nishimura RA, Tajik AJ, et al. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. *Circulation* 1994;90:2772-9.
107. Lapu-Bula R, Robert A, Vanoverschelde JL, et al. Relation of exercise capacity to left ventricular systolic function and diastolic filling in idiopathic or ischemic dilated cardiomyopathy. *Am J Cardiol* 1999;83:728-34.
108. Hansen A, Haass M, Kuecherer H, et al. Prognostic value of doppler echocardiographic mitral inflow patterns: Implications for risk stratification in patients with chronic congestive heart failure. *J Am Coll Cardiol* 2001;37:1049-55.
109. Hillis GS, Møller JE, Oh JK, et al. Noninvasive estimation of left ventricular filling pressure by  $E/e'$  is a powerful predictor of survival after acute myocardial infarction. *J Am Coll Cardiol* 2004;43:360-7.
110. Kleber FX, Sonntag S, Konertz W et al. Follow-up on passive cardiomyoplasty in congestive heart failure: Influence of the Acorn Cardiac Support Device on left ventricular function (abstract). *J Am Coll Cardiol* 2001;37(suppl 1):143A.

## **7. VERWENDETE ABKÜRZUNGEN**

ACE .....	Angiotensin converting enzyme
CorCap.....	Entspricht CSD, siehe dort
CSD .....	Cardiac Support Device
HLM .....	Herz-Lungen-Maschine
KHK .....	Koronare Herzerkrankung
LA.....	Linkes Atrium
LVAD.....	Left ventricular assist device
LVEDD.....	Linksventrikulärer enddiastolischer Diameter
LVEDP .....	Linksventrikulärer enddiastolischer Druck
LVEF .....	Linksventrikuläre Ejektionsfraktion
LVESD .....	Linksventrikulärer endsystolischer Diameter
LVL D .....	Linksventrikuläre diastolische lange Achse
MI .....	Mitralklappeninsuffizienz
MKR.....	Mitralklappenrekonstruktion
MKE .....	Mitralklappenersatz
NYHA.....	New York Heart Association
PAP <sub>sys</sub> .....	Systolischer Pulmonaldruck
RAAS .....	Renin-Angiotensin-Aldosteron-System
RR.....	Blutdruck
TI .....	Trikuspidalklappeninsuffizienz
VO <sub>2</sub> max .....	Maximale Sauerstoffaufnahme